Published in Expert Opin Ther Targets on March 23, 2012
Celastrol inhibits gastric cancer growth by induction of apoptosis and autophagy. BMB Rep (2014) 1.12
CD44 expression denotes a subpopulation of gastric cancer cells in which Hedgehog signaling promotes chemotherapy resistance. Clin Cancer Res (2014) 0.95
Clinical management of advanced gastric cancer: the role of new molecular drugs. World J Gastroenterol (2014) 0.92
Advances in Targeting HER3 as an Anticancer Therapy. Chemother Res Pract (2012) 0.90
Expression of the EGF family in gastric cancer: downregulation of HER4 and its activating ligand NRG4. PLoS One (2014) 0.90
Activation of abl family kinases in solid tumors. Genes Cancer (2012) 0.89
Brain-only metastatic breast cancer is a distinct clinical entity characterised by favourable median overall survival time and a high rate of long-term survivors. Br J Cancer (2012) 0.87
Targeting Notch signaling by γ-secretase inhibitor I enhances the cytotoxic effect of 5-FU in gastric cancer. Clin Exp Metastasis (2015) 0.85
Chemotherapy Resistance in Diffuse-Type Gastric Adenocarcinoma Is Mediated by RhoA Activation in Cancer Stem-Like Cells. Clin Cancer Res (2015) 0.83
Superior antitumor activity of nanoparticle albumin-bound paclitaxel in experimental gastric cancer. PLoS One (2013) 0.83
Prognostic role of lemur tyrosine kinase 3 in postoperative gastric cancer. Mol Clin Oncol (2014) 0.76
URI promotes gastric cancer cell motility, survival, and resistance to adriamycin in vitro. Am J Cancer Res (2016) 0.75
Role of Rac1 pathway in epithelial-to-mesenchymal transition and cancer stem-like cell phenotypes in gastric adenocarcinoma. Mol Cancer Res (2017) 0.75
Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis. Lancet Oncol (2010) 13.25
Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status. J Clin Oncol (2011) 8.66
Second-line treatment of advanced non-small cell lung cancer. J Thorac Oncol (2008) 3.95
Phase III randomized trial of FOLFIRI versus FOLFOX4 in the treatment of advanced colorectal cancer: a multicenter study of the Gruppo Oncologico Dell'Italia Meridionale. J Clin Oncol (2005) 3.93
Chronic inflammation and oxidative stress in human carcinogenesis. Int J Cancer (2007) 3.45
Digital karyotyping identifies thymidylate synthase amplification as a mechanism of resistance to 5-fluorouracil in metastatic colorectal cancer patients. Proc Natl Acad Sci U S A (2004) 3.35
ZD6474, an orally available inhibitor of KDR tyrosine kinase activity, efficiently blocks oncogenic RET kinases. Cancer Res (2002) 3.33
KRAS, BRAF, PIK3CA, and PTEN mutations: implications for targeted therapies in metastatic colorectal cancer. Lancet Oncol (2010) 3.12
First-line erlotinib followed by second-line cisplatin-gemcitabine chemotherapy in advanced non-small-cell lung cancer: the TORCH randomized trial. J Clin Oncol (2012) 3.04
Addition of cetuximab to chemotherapy as first-line treatment for KRAS wild-type metastatic colorectal cancer: pooled analysis of the CRYSTAL and OPUS randomised clinical trials. Eur J Cancer (2012) 2.79
Randomized phase III trial of gemcitabine plus cisplatin compared with single-agent gemcitabine as first-line treatment of patients with advanced pancreatic cancer: the GIP-1 study. J Clin Oncol (2010) 2.69
A meta-analysis on the interaction between HER-2 expression and response to endocrine treatment in advanced breast cancer. Clin Cancer Res (2005) 2.60
Implications for KRAS status and EGFR-targeted therapies in metastatic CRC. Nat Rev Clin Oncol (2009) 2.48
Prospective study of gefitinib in epidermal growth factor receptor fluorescence in situ hybridization-positive/phospho-Akt-positive or never smoker patients with advanced non-small-cell lung cancer: the ONCOBELL trial. J Clin Oncol (2007) 2.48
Phase II trial of cetuximab in combination with fluorouracil, leucovorin, and oxaliplatin in the first-line treatment of metastatic colorectal cancer. J Clin Oncol (2007) 2.47
Expression of vascular endothelial growth factor (VEGF) and epidermal growth factor receptor (EGFR) is an independent prognostic indicator of worse outcome in gastric cancer patients. Ann Surg Oncol (2007) 2.47
Definition of rapid virologic response with a highly sensitive real-time PCR-based HCV RNA assay in peginterferon alfa-2a plus ribavirin response-guided therapy. J Hepatol (2010) 2.35
Epidermal growth factor receptor (EGFR) expression is associated with a worse prognosis in gastric cancer patients undergoing curative surgery. World J Surg (2007) 2.24
Implication of the insulin-like growth factor-IR pathway in the resistance of non-small cell lung cancer cells to treatment with gefitinib. Clin Cancer Res (2007) 2.22
Epidermal growth factor receptor gene copy number and clinical outcome of metastatic colorectal cancer treated with panitumumab. J Clin Oncol (2007) 2.19
Prospective evaluation of major vascular events in patients with nonsmall cell lung carcinoma treated with cisplatin and gemcitabine. Cancer (2005) 2.19
Intrapatient cetuximab dose escalation in metastatic colorectal cancer according to the grade of early skin reactions: the randomized EVEREST study. J Clin Oncol (2012) 2.02
Expression of epidermal growth factor receptor correlates with disease relapse and progression to androgen-independence in human prostate cancer. Clin Cancer Res (2002) 2.01
Prognostic significance of epidermal growth factor receptor expression in colon cancer patients undergoing curative surgery. Ann Surg Oncol (2006) 2.01
Optimized granulocyte colony-stimulating factor prophylaxis in adult cancer patients: from biological principles to clinical guidelines. Expert Opin Ther Targets (2012) 1.99
Counting alleles to predict recurrence of early-stage colorectal cancers. Lancet (2002) 1.96
Crystal structure of the OXA-48 beta-lactamase reveals mechanistic diversity among class D carbapenemases. Chem Biol (2009) 1.93
Elevated perioperative serum vascular endothelial growth factor levels in patients with colon carcinoma. Cancer (2004) 1.90
Combined CD133/CD44 expression as a prognostic indicator of disease-free survival in patients with colorectal cancer. Arch Surg (2012) 1.86
Detection of KRAS mutations in colorectal carcinoma patients with an integrated PCR/sequencing and real-time PCR approach. Pharmacogenomics (2010) 1.68
Vascular endothelial growth factor in pleural fluid for differential diagnosis of benign and malignant origin and its clinical applications. Interact Cardiovasc Thorac Surg (2010) 1.65
The effects of cetuximab alone and in combination with radiation and/or chemotherapy in lung cancer. Clin Cancer Res (2005) 1.64
Randomized trial of intravenous iron supplementation in patients with chemotherapy-related anemia without iron deficiency treated with darbepoetin alpha. J Clin Oncol (2008) 1.61
Factorial phase III randomised trial of rofecoxib and prolonged constant infusion of gemcitabine in advanced non-small-cell lung cancer: the GEmcitabine-COxib in NSCLC (GECO) study. Lancet Oncol (2007) 1.60
Adjuvant chemoradiotherapy in patients with stage III or IV radically resected gastric cancer: a pilot study. Arch Surg (2010) 1.57
Vascular endothelial growth factor receptor-1 contributes to resistance to anti-epidermal growth factor receptor drugs in human cancer cells. Clin Cancer Res (2008) 1.56
Combination of a selective cyclooxygenase-2 inhibitor with epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 and protein kinase A antisense causes cooperative antitumor and antiangiogenic effect. Clin Cancer Res (2003) 1.55
Upregulated stromal EGFR and vascular remodeling in mouse xenograft models of angiogenesis inhibitor-resistant human lung adenocarcinoma. J Clin Invest (2011) 1.52
CAU-1, a subclass B3 metallo-beta-lactamase of low substrate affinity encoded by an ortholog present in the Caulobacter crescentus chromosome. Antimicrob Agents Chemother (2002) 1.52
Quality of life, fatigue and depression in Italian long-term breast cancer survivors. Support Care Cancer (2012) 1.49
Cetuximab plus FOLFOX-4 in untreated patients with advanced colorectal cancer: a Gruppo Oncologico dell'Italia Meridionale Multicenter phase II study. Oncology (2011) 1.48
Driver mutations and differential sensitivity to targeted therapies: a new approach to the treatment of lung adenocarcinoma. Cancer Treat Rev (2010) 1.45
ALK inhibitors in the treatment of advanced NSCLC. Cancer Treat Rev (2013) 1.43
Enhancement of antitumor activity of ionizing radiation by combined treatment with the selective epidermal growth factor receptor-tyrosine kinase inhibitor ZD1839 (Iressa). Clin Cancer Res (2002) 1.43
First-line chemotherapy vs bowel tumor resection plus chemotherapy for patients with unresectable synchronous colorectal hepatic metastases. Arch Surg (2008) 1.41
Combined targeting of EGFR-dependent and VEGF-dependent pathways: rationale, preclinical studies and clinical applications. Nat Clin Pract Oncol (2008) 1.39
Early skin toxicity as a predictive factor for tumor control in hepatocellular carcinoma patients treated with sorafenib. Oncologist (2010) 1.35
Prognostic significance of circulating IL-10 and IL-6 serum levels in colon cancer patients undergoing surgery. Clin Immunol (2002) 1.33
Epidemiological and clinical burden of chronic hepatitis B virus/hepatitis C virus infection. A multicenter Italian study. J Hepatol (2003) 1.32
Intrinsic and acquired resistance to EGFR inhibitors in human cancer therapy. Endocr Relat Cancer (2005) 1.30
The use of xenograft models for the selection of cancer treatments with the EGFR as an example. Crit Rev Oncol Hematol (2008) 1.30
Development of a second version of the Cobas AmpliPrep/Cobas TaqMan hepatitis C virus quantitative test with improved genotype inclusivity. J Clin Microbiol (2011) 1.29
The tyrosine kinase inhibitor ZD6474 blocks proliferation of RET mutant medullary thyroid carcinoma cells. Endocr Relat Cancer (2010) 1.28
Predictive value of epidermal growth factor receptor expression for first-line chemotherapy plus cetuximab in patients with head and neck and colorectal cancer: analysis of data from the EXTREME and CRYSTAL studies. Eur J Cancer (2012) 1.27
Erlotinib in non-small cell lung cancer treatment: current status and future development. Oncologist (2007) 1.26
Guideline on the requirements of external quality assessment programs in molecular pathology. Virchows Arch (2012) 1.24
Pharmacogenomic and pharmacoproteomic studies of cetuximab in metastatic colorectal cancer: biomarker analysis of a phase I dose-escalation study. J Clin Oncol (2010) 1.23
Linkage analysis in keratoconus: replication of locus 5q21.2 and identification of other suggestive Loci. Invest Ophthalmol Vis Sci (2008) 1.23
Radiofrequency ablation of 40 lung neoplasms: preliminary results. AJR Am J Roentgenol (2004) 1.23
Key cancer cell signal transduction pathways as therapeutic targets. Eur J Cancer (2006) 1.22
Protein kinase A as target for novel integrated strategies of cancer therapy. Ann N Y Acad Sci (2002) 1.21
Primary and acquired resistance to anti-EGFR targeted drugs in cancer therapy. Differentiation (2007) 1.19
Synergistic effects of metformin treatment in combination with gefitinib, a selective EGFR tyrosine kinase inhibitor, in LKB1 wild-type NSCLC cell lines. Clin Cancer Res (2013) 1.15
Targeting EGFR in pancreatic cancer treatment. Curr Drug Targets (2012) 1.15
Prognostic vs predictive molecular biomarkers in colorectal cancer: is KRAS and BRAF wild type status required for anti-EGFR therapy? Cancer Treat Rev (2010) 1.15
Dasatinib: an anti-tumour agent via Src inhibition. Curr Drug Targets (2011) 1.15
Synergistic antitumor activity of sorafenib in combination with epidermal growth factor receptor inhibitors in colorectal and lung cancer cells. Clin Cancer Res (2010) 1.15
Increased TGF-α as a mechanism of acquired resistance to the anti-EGFR inhibitor cetuximab through EGFR-MET interaction and activation of MET signaling in colon cancer cells. Clin Cancer Res (2013) 1.14
Determination of molecular marker expression can predict clinical outcome in colon carcinomas. Clin Cancer Res (2004) 1.14
Elevated serum levels of interleukin-8 in advanced non-small cell lung cancer patients: relationship with prognosis. J Interferon Cytokine Res (2002) 1.13
Antitumor activity of bortezomib in human cancer cells with acquired resistance to anti-epidermal growth factor receptor tyrosine kinase inhibitors. Lung Cancer (2011) 1.13
Crystal structure of the narrow-spectrum OXA-46 class D beta-lactamase: relationship between active-site lysine carbamylation and inhibition by polycarboxylates. Antimicrob Agents Chemother (2010) 1.13
Docetaxel as salvage therapy in advanced gastric cancer: a phase II study of the Gruppo Oncologico Italia Meridionale (G.O.I.M.). Anticancer Res (2003) 1.11
Antitumor activity of pimasertib, a selective MEK 1/2 inhibitor, in combination with PI3K/mTOR inhibitors or with multi-targeted kinase inhibitors in pimasertib-resistant human lung and colorectal cancer cells. Int J Cancer (2013) 1.10
Investigation of two dosing schedules of vandetanib (ZD6474), an inhibitor of vascular endothelial growth factor receptor and epidermal growth factor receptor signaling, in combination with irinotecan in a human colon cancer xenograft model. Clin Cancer Res (2007) 1.09
Overcoming resistance to molecularly targeted anticancer therapies: Rational drug combinations based on EGFR and MAPK inhibition for solid tumours and haematologic malignancies. Drug Resist Updat (2007) 1.08
Expression and prognostic value of VEGFR-2, PDGFR-β, and c-Met in advanced hepatocellular carcinoma. J Exp Clin Cancer Res (2013) 1.08
TORCH study: how much longer should we continue to use erlotinib in unselected patients with non-small-cell lung cancer? J Clin Oncol (2012) 1.07
Combining targeted therapies and drugs with multiple targets in the treatment of NSCLC. Oncologist (2006) 1.06
Is complete mesocolic excision with central vascular ligation safe and effective in the surgical treatment of right-sided colon cancers? A prospective study. Int J Colorectal Dis (2013) 1.05
Novel toll-like receptor 9 agonist induces epidermal growth factor receptor (EGFR) inhibition and synergistic antitumor activity with EGFR inhibitors. Clin Cancer Res (2006) 1.05
Cooperative antitumor effect of multitargeted kinase inhibitor ZD6474 and ionizing radiation in glioblastoma. Clin Cancer Res (2005) 1.04
Supportive care in patients with advanced non-small-cell lung cancer. Br J Cancer (2003) 1.04
Citrate anticoagulation in continuous venovenous hemodiafiltration: a metabolic challenge. Intensive Care Med (2002) 1.03
EGFR-targeted therapy. Exp Cell Res (2011) 1.03
COBAS AmpliPrep-COBAS TaqMan hepatitis B virus (HBV) test: a novel automated real-time PCR assay for quantification of HBV DNA in plasma. J Clin Microbiol (2007) 1.02